Grant: CIHR Fellowship
University of Calgary
$135,000.00
Oncolytic rhabdovirus vaccines as an adjuvant to adoptive T cell therapy for paediatric metastatic rhabdomyosarcomas: Precision targeting, expansion and trafficking
FY 2016-17
Summary
A childhood cancer diagnosis is a tragic, seemingly unfair, reality for nearly 1000 families in Canada each year. Innovations in treatment have been able to increase the odds of beating a paediatric cancer, but this success is a double edged-sword. Many of these treatment make kids unimaginably sick. These therapies can be so toxic that they result in life-long disabilities in cognition, fertility, and even the formation of cancer again. Further, some children's cancers we are just not good at treating at all. For example, rhabdomyosarcomas that have travelled to other parts of the body have an expected survival as low as 20%. We believe that childhood cancer can be combatted more effectively, and without long-term toxicities, by implementing a new form of cancer treatment called immunotherapy.
Cancers form when tumours are able to shut-down the immune system. Immunotherapy is a treatment that re-educates the body's immune system to fight the cancer by reactivating immune cells. In some adult cancers, immunotherapy is producing unprecedented durable responses (aka 'cures'). It is these types of responses that is pushing immunotherapy to the forefront of cancer treatment. In this research, we will evaluate if these responses can be achieved in childhood cancers, starting with metastatic rhabdomyosarcomas.
Viruses are powerful tools in our arsenal against cancer. Oncolytic viruses (OVs) are live viruses engineered such that they specifically infect and kill cancer cells. Decades of work has now demonstrated that OVs are also potent activators of the immune system. However, research also demonstrates that OV therapy alone is insufficient. This proposed research will evaluate OVs as a 'booster shot' for another immunotherapy, adoptive T cell therapy (ACT), to rapidly direct immune responses to the cancer. "OV-ACT" has the potential to become an effective, non-toxic, therapy for rhabdomyosarcoma and likely other childhood cancers.
Department
Program
CIHR Fellowship
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
361580
Name
Zemp Franz J
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Oncolytic rhabdovirus vaccines as an adjuvant to adoptive T cell therapy for paediatric metastatic rhabdomyosarcomas: Precision targeting, expansion and trafficking
Programtype2
Fellowship Programs
Orgnameinp2
University of Calgary
Cihramount2
$135,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Cancer; Immunology; Immunotherapy; Oncolytic Viruses; Paediatric Cancer
Abstract
A childhood cancer diagnosis is a tragic, seemingly unfair, reality for nearly 1000 families in Canada each year. Innovations in treatment have been able to increase the odds of beating a paediatric cancer, but this success is a double edged-sword. Many of these treatment make kids unimaginably sick. These therapies can be so toxic that they result in life-long disabilities in cognition, fertility, and even the formation of cancer again. Further, some children's cancers we are just not good at treating at all. For example, rhabdomyosarcomas that have travelled to other parts of the body have an expected survival as low as 20%. We believe that childhood cancer can be combatted more effectively, and without long-term toxicities, by implementing a new form of cancer treatment called immunotherapy.
Cancers form when tumours are able to shut-down the immune system. Immunotherapy is a treatment that re-educates the body's immune system to fight the cancer by reactivating immune cells. In some adult cancers, immunotherapy is producing unprecedented durable responses (aka 'cures'). It is these types of responses that is pushing immunotherapy to the forefront of cancer treatment. In this research, we will evaluate if these responses can be achieved in childhood cancers, starting with metastatic rhabdomyosarcomas.
Viruses are powerful tools in our arsenal against cancer. Oncolytic viruses (OVs) are live viruses engineered such that they specifically infect and kill cancer cells. Decades of work has now demonstrated that OVs are also potent activators of the immune system. However, research also demonstrates that OV therapy alone is insufficient. This proposed research will evaluate OVs as a 'booster shot' for another immunotherapy, adoptive T cell therapy (ACT), to rapidly direct immune responses to the cancer. "OV-ACT" has the potential to become an effective, non-toxic, therapy for rhabdomyosarcoma and likely other childhood cancers.
Competitiondate
201611
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Zemp, Franz J
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $135,000~ $0~